Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon

Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon

Background: The attempt to manage patients with acute myeloid leukemia as outpatients has become increasingly common due to high hospitalization costs, low availability for beds and patient preference. Publications on the subject are scarce, especially in low-income regions and the safety in this p...

Full description

Bibliographic Details
Main Authors:	Amanda Lopes Maia Rodrigues, Daniel Macêdo do Nascimento, Josy Marinho de Lima, Marcos Laércio Pontes Reis, Lucyana Barbosa Cardoso Leão, Murilo Chermont Azavedo, Samanta Ribeiro Muccini, Polyana Castanha da Silva, Thiago Xavier Carneiro
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2020-07-01
Series:	International Journal of Hematology-Oncology and Stem Cell Research
Subjects:	Acute myeloid leukemia; High drug dose; Chemotherapy; Outpatient care; Low-income population
Online Access:	https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1179

Similar Items

Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
by: Yasir Bashir, et al.
Published: (2015-01-01)

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
by: Sook-Kyoung Heo, et al.
Published: (2020-12-01)

Auricular Oedema and Dyshidrotic Eczema in a Patient with Acute Myeloid Leukaemia Treated with Cytarabine
by: K. Brandt, et al.
Published: (2010-10-01)

Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia
by: Stefan Hatzl, et al.
Published: (2020-02-01)

Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience
by: SV Gritsaev, et al.
Published: (2016-01-01)

Dendrogenin A synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo
by: Nizar Serhan, et al.
Published: (2020-06-01)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
by: Chen EC, et al.
Published: (2018-06-01)

miR-134 increases the antitumor effects of cytarabine by targeting Mnks in acute myeloid leukemia cells
by: Chen K, et al.
Published: (2018-05-01)

Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
by: Bista, Ranjan, et al.
Published: (2017)

The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells
by: Wenxiu Qi, et al.
Published: (2020-12-01)

Synergistic suppression effect on tumor growth of acute myeloid leukemia by combining cytarabine with an engineered oncolytic vaccinia virus
by: Peng J, et al.
Published: (2018-10-01)

Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia
by: M.C. Azevedo, et al.
Published: (2015-02-01)

Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
by: Ciera L. Patzke, et al.
Published: (2020-02-01)

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
by: Jorge E. Cortes, et al.
Published: (2020-07-01)

Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo
by: Yingyu Chen, et al.
Published: (2018-08-01)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
by: Prajwal Boddu, et al.
Published: (2018-09-01)

Model based characterization of pharmacokinetic interaction between voriconazole and cytarabine in patients with acute myeloid leukemia
by: Ματθιός, Ανδρέας
Published: (2014)

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
by: Harinder Gill, et al.
Published: (2020-05-01)

TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE
by: Maël Heiblig, et al.
Published: (2016-01-01)

A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
by: Wei Guoqing, et al.
Published: (2011-11-01)

THE OVERVIEW OF THE MAIN ST AGES OF OUTPATIENT CARE IN RUSSIA
by: O. V. Gridnev
Published: (2015-01-01)

Evaluation of the impact of single-nucleotide polymorphisms on treatment response, survival and toxicity with cytarabine and anthracyclines in patients with acute myeloid leukaemia: a systematic review protocol
by: Taynah Cascaes Puty, et al.
Published: (2019-05-01)

Low-Dose Cytarabine versus Best Supportive Care for Patients with Acute Myeloid Leukaemia Unfit for the Standard of Care: Egyptian Centre Experience
by: Amrallah Mohammed, et al.
Published: (2021-07-01)

Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia
by: Axel H. Schönthal, et al.
Published: (2021-07-01)

MALAT1 knockdown inhibits proliferation and enhances cytarabine chemosensitivity by upregulating miR-96 in acute myeloid leukemia cells
by: Ning Hu, et al.
Published: (2019-04-01)

Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia
by: Hui‐Jen Tsai, et al.
Published: (2021-05-01)

Role of CD19 and specific KIT‐D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities
by: Biao Wang, et al.
Published: (2021-02-01)

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
by: Lalit S Raut
Published: (2015-01-01)

Early experience with the vaginoscopic approach to outpatient microhysteroscopy.
by: Okeahialam, Magella G., et al.
Published: (2009)

Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia
by: Dou L, et al.
Published: (2019-06-01)

Relationships between Personal Traits, Emotional Intelligence, Internal Marketing, Service Management, and Customer Orientation in Korean Outpatient Department Nurses
by: Bogyun Kim, MSN, RN, et al.
Published: (2016-03-01)

Comparing Transcutaneous to Serum Bilirubin after Phototherapy in the Outpatient Setting
by: Makarova, Natasha
Published: (2017)

Myeloid Sarcoma in an Eyelid That Developed during Chemotherapy for Acute Myeloid Leukemia
by: Hyera Kang, et al.
Published: (2016-01-01)

Anterior myeloid sarcoma revealing acute myeloid leukemia: Case report
by: H. Slimani, et al.
Published: (2016-07-01)

Chidamide Enhances the Cytotoxicity of Cytarabine and Sorafenib in Acute Myeloid Leukemia Cells by Modulating H3K9me3 and Autophagy Levels
by: He Huang, et al.
Published: (2019-12-01)

A comparative study of idarubicin 12 mg/m2 and 8 mg/m2 combined with cytarabine as the first induction regimen for adult acute myeloid leukemia patients
by: Zhou L, et al.
Published: (2016-02-01)

Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study
by: Xiaoyang Li, et al.
Published: (2019-08-01)

QUALITY OF LIFE IN HYPERTENSIVES RECEIVING OUTPATIENT TREATMENT
by: Natália Carolina Mian, et al.
Published: (2012-09-01)

Outpatient (Same-day care) Neuroangiography and Neurointervention
by: Yun-Gyeong Jeong, et al.
Published: (2012-02-01)

Osteoporosis: diagnosis, prevention and treatment in outpatient setting
by: Mark Pavlovich Rubin, et al.
Published: (2011-01-01)